Operating Data

Acorda Therapeutics Inc

Acorda Therapeutics Inc (ACOR)

$8.04
0.07 (+0.88%)
Year
A/P
2013
Actual
2014
Actual
2015
Actual
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
Revenue 336.43401.48492.66519.60588.29471.43192.41186.53180.84175.32169.97164.78
Revenue (%)
EBITDA 38.0354.9660.754.44127.68108.50-82.2510.7010.3710.069.759.45
EBITDA (%)
EBIT 31.0346.4945.74-17.14104.4497.02-116.821.171.141.101.071.04
EBIT (%)
Depreciation 7.008.4715.0121.5823.2311.4834.579.539.238.958.688.41
Depreciation (%)




EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT)
EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income)
EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization
EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company
(1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments),
(2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill)
(3*) collections of assets (by ignoring depreciation of assets)
(4*) different takeover histories (by ignoring amortization often stemming from goodwill)